Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The lung microbiome: progress and promise
Samantha A. Whiteside, … , John E. McGinniss, Ronald G. Collman
Samantha A. Whiteside, … , John E. McGinniss, Ronald G. Collman
Published August 2, 2021
Citation Information: J Clin Invest. 2021;131(15):e150473. https://doi.org/10.1172/JCI150473.
View: Text | PDF
Review Article has an altmetric score of 16

The lung microbiome: progress and promise

  • Text
  • PDF
Abstract

The healthy lung was long thought of as sterile, but recent advances using molecular sequencing approaches have detected bacteria at low levels. Healthy lung bacteria largely reflect communities present in the upper respiratory tract that enter the lung via microaspiration, which is balanced by mechanical and immune clearance and likely involves limited local replication. The nature and dynamics of the lung microbiome, therefore, differ from those of ecological niches with robust self-sustaining microbial communities. Aberrant populations (dysbiosis) have been demonstrated in many pulmonary diseases not traditionally considered microbial in origin, and potential pathways of microbe-host crosstalk are emerging. The question now is whether and how dysbiotic microbiota contribute to initiation or perpetuation of injury. The fungal microbiome and virome are less well studied. This Review highlights features of the lung microbiome, unique considerations in studying it, examples of dysbiosis in selected disease, emerging concepts in lung microbiome–host interactions, and critical areas for investigation.

Authors

Samantha A. Whiteside, John E. McGinniss, Ronald G. Collman

×

Figure 2

Nature and potential impact of the lung microbiome in health and disease.

Options: View larger image (or click on image) Download as PowerPoint
Nature and potential impact of the lung microbiome in health and disease...
In healthy lungs, the bacterial communities (colored shapes) have low biomass and are largely derived passively from the URT. Low-biomass communities associate with a balanced immune tone that promotes mucosal regulatory T cells (Tregs) and Th17 readiness. Tregs and Th17 cells may promote a basal-level immune tone that is necessary for clearance of encountered pathogens without pathological inflammatory responses. In disease, a dysbiotic microbiota may activate innate and adaptive immune responses that promote immunopathology. This inflammatory state can lead to epithelial fibroproliferation, promotion of immune cell immigration to the lung in response to cytokine and chemokine elaboration, and heightened Th2 immune tone, among other potential pathological mechanisms. Mediators include microbial metabolites such as short-chain fatty acids (SCFAs), as well as pattern recognition receptor (PRR) ligands by which even nonviable bacteria may trigger responses. The virome and mycobiome in health and lung disease remain understudied.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Posted by 12 X users
On 1 Facebook pages
140 readers on Mendeley
See more details